More patients treated with dupilumab experienced sustained disease remission and itch reduction at week 36 compared with those who received placebo. The Food and Drug Administration (FDA) has approved ...

A Prescription Drug User Fee Act target date of June 20, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics ...

DEAR DR. ROACH: I have had an autoimmune disease called bullous pemphigoid for the past four years. I originally was treated with prednisone therapy for over a year, which was then tapered and changed ...

DEAR DR. ROACH: I am a 73-year-old woman who is in otherwise good health, but I was diagnosed with bullous pemphigoid, a rare autoimmune disease, in January 2022. I have been treated by three ...

The U.S. Food and Drug Administration (FDA) on Friday approved Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Sanofi SA’s (NASDAQ:SNY) Dupixent (dupilumab) for adult patients with bullous pemphigoid ...

Dupixent may become the first targeted treatment for bullous pemphigoid in the U.S., pending FDA approval by June 2025. Regeneron Pharmaceuticals, Inc. and Sanofi announced that the FDA has accepted a ...

Please provide your email address to receive an email when new articles are posted on . If approved, Dupixent would be the first and only targeted medicine to treat bullous pemphigoid in the U.S. The ...

Study met the primary and all key secondary endpoints in adults with moderate-to-severe disease; five times more patients achieved sustained disease remission with Dupixent than placebo Dupixent is ...

Anti-BP180 antibody levels demonstrated a moderate to strong correlation with the severity of bullous pemphigoid (BP), in a meta-analysis highlighting the potential of anti-BP180 as a tool to monitor ...